Moroctocog Alfa

證據等級: L5

預測適應症: 8 個

MOROCTOCOG ALFA: From Hemophilia A to Primary Release Disorder of Platelets

One-Sentence Summary

Moroctocog alfa is a B-domain–deleted recombinant human Factor VIII (rFVIII) replacement product, used for the treatment and prevention of bleeding in Hemophilia A (congenital Factor VIII deficiency). The TxGNN model's top-ranked prediction suggests possible effectiveness for Primary Release Disorder of Platelets, but this is currently supported only by 7 clinical trials — none of which actually enrolled patients with this disease — and no relevant literature, indicating weak and likely spurious evidential support.

Quick Overview

Item	Content
Original Indication	Hemophilia A (congenital Factor VIII deficiency) — inferred from drug class; no German market license data available to confirm
Predicted New Indication	Primary Release Disorder of Platelets
TxGNN Prediction Score	99.97%
Evidence Level	L4
Germany Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (data gap). Based on known information, moroctocog alfa is a B-domain-deleted recombinant human Factor VIII replacement product; its efficacy in Hemophilia A has been well established, and mechanistically it works by restoring FVIII coagulation activity in patients who lack sufficient endogenous factor.

Primary Release Disorder of Platelets, however, is a platelet granule secretion defect — bleeding results from the platelets' inability to release their storage granule contents upon activation, not from a deficiency of a plasma coagulation factor. FVIII supplementation does not address this underlying secretory defect, so the mechanistic rationale for this prediction is weak.

This is corroborated by the supporting evidence itself: all 7 cited clinical trials were graded "C" for relevance, and none actually studied patients with a platelet release disorder. They instead cover Hemophilia A trials of unrelated FVIII products (BIVV001, BAX855), artificial liver support in acute-on-chronic liver failure, portal vein hemostasis during TIPS procedures, post-COVID-vaccination coagulation studies, and coagulation profiles in AML. This pattern suggests the TxGNN association likely reflects broad semantic proximity between "bleeding disorder" concepts in the knowledge graph rather than a genuine, drug-specific pharmacological link — consistent with the reviewer note flagging a possible database mismatch.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04161495	Phase 3	Completed	159	BIVV001 (PEGylated rFVIIIFc-VWF-XTEN) prophylaxis in severe Hemophilia A ≥12 yrs — not a platelet release disorder population
NCT01913405	Phase 3	Completed	30	PEGylated rFVIII (BAX 855) in severe Hemophilia A undergoing surgery — unrelated population
NCT07329036	N/A	Recruiting	25	Artificial liver support system (DPMAS+TPE) in acute-on-chronic liver failure — no direct link
NCT07439939	N/A	Recruiting	45	Systemic/portal hemostasis during TIPS placement — no direct link
NCT07400848	N/A	Recruiting	200	Post-COVID-19-vaccination syndrome symptom/lab evaluation — no direct link
NCT07343687	N/A	Not yet recruiting	80	Coagulation profiles in newly diagnosed AML on induction chemotherapy — no direct link

(All 7 trials retrieved were graded "C" relevance; none enrolled patients with a primary platelet release disorder.)

Literature Evidence

Currently no related literature available.

Germany Market Information

No German market authorizations found. taiwan_regulatory data indicates the drug is not marketed (0 licenses on file), so no product/dosage-form/indication details can be provided.

Safety Considerations

Please refer to the package insert for safety information.

(Note: German label warnings/contraindications (DG001) and MOA detail (DG002) are flagged as data gaps in this evidence pack — DG001 is a Blocking gap that prevents a full S1 safety review.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked TxGNN prediction (Primary Release Disorder of Platelets) lacks any mechanistically relevant clinical or literature evidence — all cited trials involve unrelated patient populations and different investigational products. The evidence pattern is more consistent with a knowledge-graph semantic artifact than a true pharmacological signal.

To proceed, the following is needed:

Resolve Blocking data gap DG001 (German label warnings/contraindications) before any S1 safety review can proceed
Resolve High-severity data gap DG002 (confirmed MOA) to support mechanistic-relevance analysis
If this indication is pursued further, dedicated preclinical/translational evidence demonstrating a role for FVIII beyond coagulation in platelet granule release would be required
Separately worth noting: among the 8 TxGNN-predicted indications reviewed for moroctocog alfa in this batch, acquired coagulation factor deficiency (rank 4) is mechanistically far more plausible (FVIII replacement is directly relevant to acquired Hemophilia A) and reached evidence level L3 / decision stage S2 with a "Research Question" recommendation. However, most of its supporting trials used porcine FVIII (Obizur/susoctocog alfa) rather than moroctocog alfa itself, so direct evidence transfer remains uncertain — this candidate merits a separate, dedicated evaluation rather than being pursued under the current top-ranked indication.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.